The Effect of Anti-IL-21 and Liraglutide in Newly Diagnosed Type 1 Diabetes
Recruiting T1D UK Sites: Bristol, Birmingham, Cardiff, London QMUL, Newcastle, Sheffield, Swansea
Other participating sites: Belfast, Blackburn, London Imperial College, Plymouth Stevenage
This study will investigate if a new drug Anti-IL-21 when given together with another drug marketed for type 2 diabetes called liraglutide can preserve the beta cells in subjects diagnosed with type 1 diabetes.
The study is for adults aged 18-45 years who have been diagnosed with type 1 diabetes within 20 weeks of the screening visit.